T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$1.66B |
| 2 |
Canadian Natural Resources
CNQ
|
+$759M |
| 3 |
Becton Dickinson
BDX
|
+$735M |
| 4 |
Ashland
ASH
|
+$669M |
| 5 |
Keysight
KEYS
|
+$573M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RTX Corp
RTX
|
+$1.73B |
| 2 |
Ecolab
ECL
|
+$1.17B |
| 3 |
Crown Castle
CCI
|
+$906M |
| 4 |
Phillips 66
PSX
|
+$775M |
| 5 |
Gilead Sciences
GILD
|
+$756M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 19.84% |
| 2 | Consumer Discretionary | 13.93% |
| 3 | Financials | 13.41% |
| 4 | Industrials | 12.4% |
| 5 | Technology | 9.56% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
301
Brunswick
BC
$5.15B
| $358M | 0.08% |
6,990,285
-367,826
| -5% | -$17.2M |
|
302
GSK
GSK
$101B
| $358M | 0.08% |
6,702,530
+40,376
| +0.6% | +$2.26M |
|
303
Accenture
ACN
$109B
| $357M | 0.08% |
4,002,475
-286,381
| -7% | -$23.8M |
|
304
ConocoPhillips
COP
$152B
| $357M | 0.08% |
5,172,777
-129,530
| -2% | -$9.04M |
|
305
Ball Corp
BALL
$16.6B
| $356M | 0.08% |
10,447,062
-527,150
| -5% | -$17.4M |
|
306
Viavi Solutions
VIAV
$10.6B
| $355M | 0.08% |
45,549,898
-132,393
| -0.3% | -$987K |
|
307
Analog Devices
ADI
$188B
| $352M | 0.07% |
6,347,731
-762,480
| -11% | -$38.9M |
|
308
Teva Pharmaceuticals
TEVA
$42.6B
| $350M | 0.07% |
6,084,706
+755,668
| +14% | +$42.1M |
|
309
Essex Property Trust
ESS
$18.1B
| $349M | 0.07% |
1,690,698
+3,185
| +0.2% | +$631K |
|
310
Rayonier
RYN
$6.43B
| $349M | 0.07% |
13,767,663
+10,054,587
| +271% | +$270M |
|
311
Genuine Parts
GPC
$18.4B
| $347M | 0.07% |
3,255,601
+20,210
| +0.6% | +$1.98M |
|
|
WFM
312
DELISTED
Whole Foods Market Inc
WFM
| $345M | 0.07% |
6,833,707
-407,602
| -6% | -$18M |
|
|
CB
313
DELISTED
CHUBB CORPORATION
CB
| $341M | 0.07% |
3,296,445
+29,861
| +0.9% | +$2.97M |
|
314
Equity Residential
EQR
$24.3B
| $341M | 0.07% |
4,747,775
+14
| +0% | +$969 |
|
315
Zillow
ZG
$7.48B
| $341M | 0.07% |
9,656,520
+5,573,283
| +136% | +$204M |
|
|
DGI
316
DELISTED
DigitalGlobe Inc.
DGI
| $339M | 0.07% |
10,959,983
-2,451,200
| -18% | -$69M |
|
317
Ford
F
$55.1B
| $339M | 0.07% |
21,861,227
+427,750
| +2% | +$6.3M |
|
318
RH
RH
$3.42B
| $338M | 0.07% |
3,525,329
-1,421,073
| -29% | -$119M |
|
|
CVD
319
DELISTED
COVANCE INC.
CVD
| $338M | 0.07% |
3,252,502
-1,223,319
| -27% | -$115M |
|
320
Federal Realty Investment Trust
FRT
$10.2B
| $334M | 0.07% |
2,503,076
-78,495
| -3% | -$10.2M |
|
321
Liberty Global Class A
LBTYA
$3.54B
| $332M | 0.07% |
8,019,288
+1,872,520
| +30% | +$71.8M |
|
322
Stratasys
SSYS
$772M
| $331M | 0.07% |
3,980,047
-549,639
| -12% | -$56.2M |
|
323
C.H. Robinson
CHRW
$17.3B
| $330M | 0.07% |
4,404,989
-158,165
| -3% | -$11.3M |
|
324
Delta Air Lines
DAL
$58.9B
| $328M | 0.07% |
6,659,117
-7,597,319
| -53% | -$320M |
|
325
McCormick & Company Non-Voting
MKC
$14.2B
| $327M | 0.07% |
8,808,782
+42,264
| +0.5% | +$1.51M |
|
Similar funds
T. Rowe Price Associates's Q4 2014 Portfolio in Review
As of Q4 2014, T. Rowe Price Associates held 2,627 positions worth $471B, up 2.8% from $458B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
T. Rowe Price Associates's Q4 2014 filing shows 87 new, 929 increased, 999 reduced and 89 closed positions. Its largest new stake was Keysight: 17,553,953 shares worth $593M. The largest sale was RTX Corp, an estimated $1.73B.
By sector, the portfolio is most concentrated in Healthcare at 20% of assets, up from 18% a quarter earlier, followed by Consumer Discretionary and Financials.
- T. Rowe Price Associates's largest Q4 2014 buy was Keysight: 17,553,953 shares worth $593M.
- T. Rowe Price Associates added most to Allergan plc in Q4 2014, an estimated $1.66B increase.
- T. Rowe Price Associates's biggest Q4 2014 reduction was RTX Corp, cutting an estimated $1.73B.
- T. Rowe Price Associates fully exited ATHLON ENERGY INC COM in Q4 2014, selling an estimated $499M.
- T. Rowe Price Associates's ten largest holdings make up 13% of its $471B portfolio in Q4 2014.
- T. Rowe Price Associates opened 87 new positions and closed 89 in Q4 2014.
- T. Rowe Price Associates's portfolio value rose 2.8% quarter-over-quarter to $471B.
Based on T. Rowe Price Associates's 13F filing for Q4 2014, filed 13 Feb 2015.